BioCryst Pharmaceuticals | BCRX - 现金及等价物



金融业
股票价格
USD
资产
USD 557.85M
现金及等价物
USD 154.97M
销售成本
USD 3.84M
流动资产
USD 484.68M
流动负债
USD 208.85M
债务
USD 828.6M
股息收益率
0
EBIT
USD 98.47M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 0.3
股本和储备
USD -454.29M
销售毛利
USD 214.41M
债务利息支出
USD 21.71M
利息收入
USD -0.13
贷款资金
USD 395.4M
市值
USD 1.79B
净收入
USD 78.4M
营业费用
USD 119.79M
营业利润
USD 98.47M
普通股股本
USD 255.27M
PE价格收益
6.84
税前利润
USD 248.02M
销售收入
USD 218.25M
销售和管理费用
USD 63.98M
股票
USD 6.06M
贸易债权人
USD 11.46M
应收帐款人
USD 110.76M


现金及等价物 更改 日
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
BioCryst Pharmaceuticals USD 154.97M 16.62M 2026-06
Chugai Pharma JPY 426.6B 29.83B 2025-12
Daiichi Sankyo JPY 449.81B 92.35B 2026-03
DBV Technologies USD 174.9M 54.3M 2026-06
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Gilead Sciences USD 7.63B 64M 2026-03
GlaxoSmithKline GBP 3.44B 292M 2026-03
Glaxosmithkline GBP 3.44B 146M 2026-03
Incyte USD 3.98B 33.45M 2026-06
Ionis Pharmaceuticals USD 350.06M 1.57B 2026-06
Karyopharm Therapeutics USD 90.85M 30.31M 2026-03
Neurocrine Biosciences USD 332.4M 65.9M 2026-06
Novavax USD 191.46M 36.9M 2026-06
PTC Therapeutics USD 1.05B 215.9M 2026-06
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Roche Holding CHF 7.55B 579M 2025-06
Sarepta Therapeutics USD 571.15M 106.7M 2026-06
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
Vertex Pharmaceuticals USD 7.85B 605.7M 2026-06